Last checked at 17 Mar 2021 15:30
SMITH & NEPHEW PLC
17 March 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
Following the announcement on 9 March 2021, regarding the awards made under the Smith & Nephew Global Share Plan 2020 of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company"), those share awards vested on 16 March 2021.
1. FINAL VESTING ON 16 MARCH 2021 OF SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2018 PERFORMANCE SHARE PROGRAMME AWARDS:
The awards were granted under the Global Share Plan 2020 on 8 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.
The following relates to all individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Final vesting on 16 March 2021 of Supplementary Awards granted under the Smith & Nephew Global Share Plan 2020 for the 2018 Performance Share Programme awards. |
Date of Transaction | 2021 - 03 - 16 |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) | Status | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | 14.0000
| 3,740 (of which 1,665 were sold and 2,075 retained) | N/A Single Transaction | 84,165.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00951%
|
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | 14.0000
| 1,781 (of which 841 were sold and 940 retained) | N/A Single Transaction | 45,298.19975 ordinary shares | 0.00512%
|
Elga Lohler (Chief HR Officer) | PDMR | 14.0000
| 2,848 (of which 1,125 were sold and 1,723 retained) | N/A Single Transaction | 106,816.00000 ordinary shares (including 3,015.00000 in ADS') | 0.01207%
|
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | 14.0000
| 2,823 (of which 963 were sold and 1,860 retained) | N/A Single Transaction | 81,517.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00921%
|
Vasant Padmanabhan (President Research & Development) | PDMR | 14.0000
| 3,207 (of which 1,089 were sold and 2,118 retained) | N/A Single Transaction | 64,620.00000 ordinary shares | 0.00730%
|
Susan Swabey (Company Secretary) | PDMR | 14.0000
| 1,255 (of which 592 were sold and 663 retained) | N/A Single Transaction | 49,225.83952 ordinary shares | 0.00556%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
Vickie Reuben
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410